1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: U.S. Tuberculosis Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. U.S. Tuberculosis Diagnostics Market, by Test Type
8.1.1 Immunological Tests
8.1.1.1. Market Revenue and Forecast
8.1.2. Molecular Diagnostics
8.1.2.1. Market Revenue and Forecast
8.1.3. Microbiological/Culture Tests
8.1.3.1. Market Revenue and Forecast
8.1.4. Radiographic & Others
8.1.4.1. Market Revenue and Forecast
9.1. U.S. Tuberculosis Diagnostics Market, by Disease Stage
9.1.1. Latent TB Infection (LTBI)
9.1.1.1. Market Revenue and Forecast
9.1.2. Active TB Disease
9.1.2.1. Market Revenue and Forecast
10.1. U.S. Tuberculosis Diagnostics Market, by End-User
10.1.1. Diagnostic & Public Health Laboratories
10.1.1.1. Market Revenue and Forecast
10.1.2. Hospitals & Clinics
10.1.2.1. Market Revenue and Forecast
10.1.3. Others (Academic/Research)
10.1.3.1. Market Revenue and Forecast
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Test Type
11.1.4.2. Market Revenue and Forecast, by Disease Stage
11.1.4.3. Market Revenue and Forecast, by End-User
12.1. epheid
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. QIAGEN N.V.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Becton, Dickinson and Company
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. (BD) Oxford Immunotec
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Abbott Laboratories
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Roche Molecular Systems, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Thermo Fisher Scientific Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. bioMérieux SA
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Hologic, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. DiaSorin S.p.A.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
